Stratified Medicine in primary Sjögren’s syndrome

Objectives of the Project

The proposal aims to further characterise the clinical significance and the underpinning pathotypes of 4 PSS subtypes. The specific objectives are:

1. To understand the natural history of the different PSS subtypes.

2. To validate the transcriptomic signatures of the PSS subtypes and re-calibrate (if necessary) for non-UK cohorts.

3. To further characterise the underpinning pathobiological profiles of the four PSS subtypes

4. To explore whether the four subtypes respond differently to treatments by reanalysing data from two clinical trials (JOQUER (hydroxychloroquine) and TRACTISS (Rituximab)

Facts and Figures

Project lead
Prof. W-F Ng
Newcastle University
FOREUM research grant: € 600.000
2018, Duration 3 years

Meet the Team

Mr. D Lendrem
Newcastle University
Prof. J-E Gottenberg
Strasbourg University
Prof. R Seror
Université Paris Sud INSERM U1184
Prof. V Devauchelle-Pensec
Brest University
Prof. A Saraux
Brest University
Hon Prof. S Bowman
University of Birmingham
Dr. F Barone
University of Birmingham
Dr. B Fisher
University of Birmingham
Assoc. Prof. G Nordmark
Uppsala University
Prof. U Landegren
Uppsala University
Prof. R Omdal
Stavanger University Hospital
Dr. M Bombardieri
Queen Mary University London

Patient Voice

One Italian (AMRER) and two Spanish (FEP and LIRE) associations of patients are involved as patient research partners (PRPs). Patient associations in France and Switzerland will be further involved.

EULAR guidelines for Patient Research Partners (PRP) inclusion have been followed. We have discussed the design of the project and the burden for patients with the PRPs integrating their feedback. PRPs will be involved in all phases of the project. PRPs will be involved in writing the patient consent forms and the clinical record forms. Patients who consent to participate the study will be asked to report any adverse effects of the therapies and exacerbation of symptoms. PRPs will help with patient recruitment and education by organizing events to make patients gaining knowledge about GCA which will empower them to actively participate in the project (e.g. leaflets about the disease and the research project, meetings, information on the PRP web sites). PRPs will be asked to constantly contribute by bringing patient perspective and experiential knowledge. They will participate to the dissemination of the results among patients and non-academic institutions.